Fig 1: IL-22BP is present in the liver and produced in the gut, and plasma levels are markedly reduced. (a) Immunohistochemical staining for IL-22BP in paraffin-embedded sections of liver from patients with alcoholic hepatitis and healthy liver and colon. Representative sections displayed. (b) Plasma IL-22BP by ELISA from the portal vein and peripheral blood in a cohort of patients with cirrhosis and in (c–e) peripheral plasma from patients with alcoholic hepatitis (AH) and controls; nonalcoholic fatty liver (NAFL) and steatohepatitis (NASH) and stable alcoholic (Alc) cirrhosis (analysis of variance, T-test, *P < 0.05,**P < 0.01, ***P < 0.001, bars represent means and SDs).
Fig 2: Low IL-22BP at diagnosis is associated with 1-year mortality. Plasma IL-22BP by ELISA. (a) Kaplan-Meier survival curve of all patients with alcoholic hepatitis stratified by plasma IL-22BP at diagnosis above or below 225 ng/mL (Log-rank test: P = 0.037). (b) The plasma IL-22BP at day 7 was compared between alcoholic hepatitis patients, who had died by day 90 and those still alive (T-test, bars display mean and SD, *P < 0.05). BP, binding protein; IL, interleukin.
Fig 3: Presence of IL-22BP sustains IL-22 receptor expression. (a) HepG2 cells stimulated with 50 ng/mL recombinant IL-22 alone or in combination with varying concentrations of recombinant IL-22BP for 4 hours. (b and c) primary human hepatocytes and HepG2 cells stimulated with 50 ng/mL recombinant IL-22 alone or in combination with 250 ng/mL recombinant IL-22BP for 24 h and followed by repeat IL-22 stimulation for 4 hours. IL-22 receptor (R) expression by quantitative polymerase chain reaction relative to GAPDH and an unstimulated control. (d) IL-22R expression by RNA sequencing and (e and f) immunohistochemistry of livers from alcoholic hepatitis patients compared with healthy liver. BP, binding protien; GAPDH, Glyceraldehyde 3-phospahte dehydrogenase; IL, Interleukin.
Supplier Page from Sino Biological, Inc. for Human IL22BP / IL22RA2 Protein (His Tag)